Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on April 30, 2025
PAIRS Foundation Unveils Free Mental Wellness App Offering Science-Backed Emotional Tools
EIN Presswire
·
April 30, 2025
The PAIRS Foundation has launched Yodi — a free, AI-powered app offering short, proven exercises to support mental, emotional, and physical well-being. FORT LAUDERDALE, FL, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- After more than 50 years of …
CARLING ADRENAL CENTER BRINGS NATIONAL ATTENTION TO PHEOCHROMOCYTOMA AND OTHER ADRENAL TUMORS WITH ANY LAB TEST NOW
EIN Presswire
·
April 30, 2025
TAMPA, FL, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- The Carling Adrenal Center is shining a spotlight on Pheochromocytoma, a rare but serious adrenal tumor that can cause life-threatening spikes in blood pressure, severe headaches, sweating, …
Florida Spine Associates Patients Reclaim Their Health and Confidence with Prescribe FIT
EIN Presswire
·
April 30, 2025
BOYNTON BEACH, FL, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- Florida Spine Associates, known for their commitment to comprehensive, patient-centered spine care, is seeing extraordinary results thanks to their new Prescribe FIT virtual health …
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
GlobeNewswire
·
April 30, 2025
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine For more information, please read Neurocrine’s announcement (link) Tokyo, Japan …
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
GlobeNewswire
·
April 30, 2025
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix …
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations
GlobeNewswire
·
April 30, 2025
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s Investor Relations (IR) team in Japan …
NewVue.ai and Smart Reporting Partner to Embed Adaptive Reporting in the Radiologist Cockpit
EIN Presswire
·
April 30, 2025
TAMPA, FL, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- NewVue.ai, a leader in cloud-native radiology workflow orchestration, and Smart Reporting, a global innovator in AI-powered diagnostic reporting, today announced a strategic integration that …
UPDATE – The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer
GlobeNewswire
·
April 30, 2025
STUDIO CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members and longtime philanthropist John O’Dwyer, who lived with myeloma for 18 …
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
GlobeNewswire
·
April 30, 2025
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on April 24, 2025 indicating that the Company’s failure to file …
AdCare Hospital Names New Executive Director to Tackle Growing Addiction Crisis Across Massachusetts
GlobeNewswire
·
April 30, 2025
WORCESTER, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- As Massachusetts continues to see waves of preventable deaths from the opioid overdose epidemic, AdCare Hospital, a longstanding provider of addiction treatment services in Worcester, MA, has named Laura …
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
GlobeNewswire
·
April 30, 2025
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery …
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
April 30, 2025
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today …
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
GlobeNewswire
·
April 30, 2025
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye …
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
GlobeNewswire
·
April 30, 2025
DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in …
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
·
April 30, 2025
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …
Best CBD Gummies of 2025: Cornbread Hemp CBD Products Help with Sleep, Pain, and Stress Relief
GlobeNewswire
·
April 30, 2025
Louisville, KY, April 30, 2025 (GLOBE NEWSWIRE) -- In a market saturated with cannabidiol (CBD) products, one company continues to lead with quality, transparency, and innovation. Cornbread Hemp has officially been named the provider of the Best CBD …
CooperCompanies Appoints Barbara Carbone to Board of Directors
GlobeNewswire
·
April 30, 2025
SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. …
Teladoc Health Reports First Quarter 2025 Results
GlobeNewswire
·
April 30, 2025
PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2025 (“First Quarter 2025”). Unless otherwise noted, percentage and …
Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining
GlobeNewswire
·
April 30, 2025
SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO”), today provided strategic, financial, and operational updates for …
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
GlobeNewswire
·
April 30, 2025
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial …